Novavax (NASDAQ:NVAX - Get Free Report) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.24, RTT News reports. The firm had revenue of $88.31 million during the quarter, compared to analysts' expectations of $85.48 million. During the same quarter in the prior year, the firm posted ($1.44) earnings per share.
Novavax Price Performance
Shares of NASDAQ:NVAX traded down $0.46 during trading hours on Monday, hitting $7.87. 6,065,978 shares of the company's stock traded hands, compared to its average volume of 4,720,579. The firm has a market capitalization of $1.26 billion, a P/E ratio of -3.48, a price-to-earnings-growth ratio of 2.85 and a beta of 2.14. The business has a fifty day moving average price of $8.51 and a 200-day moving average price of $9.95. Novavax has a 1 year low of $3.81 and a 1 year high of $23.86.
Insider Buying and Selling at Novavax
In other news, Director James F. Young sold 4,600 shares of the firm's stock in a transaction that occurred on Tuesday, December 24th. The shares were sold at an average price of $8.48, for a total transaction of $39,008.00. Following the transaction, the director now directly owns 57,160 shares of the company's stock, valued at approximately $484,716.80. This trade represents a 7.45 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Rachel K. King sold 4,150 shares of Novavax stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $9.02, for a total transaction of $37,433.00. Following the sale, the director now directly owns 14,770 shares of the company's stock, valued at $133,225.40. This represents a 21.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 14,150 shares of company stock valued at $119,641 in the last quarter. 1.00% of the stock is owned by insiders.
Analyst Ratings Changes
NVAX has been the topic of several recent research reports. BTIG Research assumed coverage on Novavax in a report on Friday. They set a "buy" rating and a $19.00 price objective on the stock. TD Cowen raised shares of Novavax to a "hold" rating in a research note on Thursday. Finally, HC Wainwright reissued a "buy" rating and issued a $19.00 price objective on shares of Novavax in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $18.00.
Get Our Latest Report on Novavax
About Novavax
(
Get Free Report)
Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
Further Reading
Before you consider Novavax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novavax wasn't on the list.
While Novavax currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
